Gilead Sciences, Inc.
GILD
$98.16
-$0.74-0.75%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.57B | 7.55B | 6.95B | 6.69B | 7.11B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.57B | 7.55B | 6.95B | 6.69B | 7.11B |
| Cost of Revenue | 1.58B | 1.57B | 1.54B | 1.55B | 1.61B |
| Gross Profit | 5.99B | 5.97B | 5.41B | 5.13B | 5.50B |
| SG&A Expenses | 1.86B | 1.41B | 1.37B | 1.36B | 1.58B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.07B | 4.38B | 4.26B | 4.38B | 4.64B |
| Operating Income | 2.50B | 3.17B | 2.69B | 2.30B | 2.48B |
| Income Before Tax | 2.17B | 956.00M | 2.05B | -4.49B | 1.65B |
| Income Tax Expenses | 385.00M | -297.00M | 438.00M | -315.00M | 237.00M |
| Earnings from Continuing Operations | 1.78B | 1.25B | 1.61B | -4.17B | 1.42B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 12.00M |
| Net Income | 1.78B | 1.25B | 1.61B | -4.17B | 1.43B |
| EBIT | 2.50B | 3.17B | 2.69B | 2.30B | 2.48B |
| EBITDA | 3.20B | 3.86B | 3.39B | 2.99B | 3.17B |
| EPS Basic | 1.43 | 1.00 | 1.29 | -3.34 | 1.15 |
| Normalized Basic EPS | 1.17 | 1.49 | 1.25 | 1.08 | 1.18 |
| EPS Diluted | 1.41 | 1.00 | 1.29 | -3.34 | 1.13 |
| Normalized Diluted EPS | 1.16 | 1.48 | 1.25 | 1.08 | 1.17 |
| Average Basic Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B |
| Average Diluted Shares Outstanding | 1.26B | 1.25B | 1.25B | 1.25B | 1.26B |
| Dividend Per Share | 0.77 | 0.77 | 0.77 | 0.77 | 0.75 |
| Payout Ratio | 54.57% | 78.45% | 60.22% | -23.74% | 65.99% |